UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000000782
Receipt number R000000939
Scientific Title Cancer therapy with vaccination using HLA-A24-restricted peptide from TOMM34:a phase I study in patients with unresectable colorectal cancer
Date of disclosure of the study information 2007/07/30
Last modified on 2008/07/30 19:14:34

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Cancer therapy with vaccination using HLA-A24-restricted peptide from TOMM34:a phase I study in patients with unresectable colorectal cancer

Acronym

TOMM34 peptide vaccination:a phase I study in patients with unresectable colorectal cancer(A24)

Scientific Title

Cancer therapy with vaccination using HLA-A24-restricted peptide from TOMM34:a phase I study in patients with unresectable colorectal cancer

Scientific Title:Acronym

TOMM34 peptide vaccination:a phase I study in patients with unresectable colorectal cancer(A24)

Region

Japan


Condition

Condition

unresectable colorectal cancer

Classification by specialty

Gastroenterology Gastrointestinal surgery

Classification by malignancy

Malignancy

Genomic information

YES


Objectives

Narrative objectives1

safety

Basic objectives2

Safety

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2


Developmental phase

Phase I


Assessment

Primary outcomes

Safety

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine Vaccine

Interventions/Control_1

vaccination

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

75 years-old >=

Gender

Male and Female

Key inclusion criteria

Performance status 0-2
HLA-A24
No response to CPT-11,5-FU, LV, Oxaliplatin, Bevacizumab
etc,

Key exclusion criteria

pregnancy
uncontrolled infection
uncontrolled cerebral metastasis
etc,

Target sample size

6


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Kanamoto Akira

Organization

Institute of Medical Science, University of Tokyo

Division name

surgery and Bioengineering

Zip code


Address

4-6-1, Shiroganedai, Minato-ku, Tokyo, Japan

TEL


Email



Public contact

Name of contact person

1st name
Middle name
Last name

Organization

Institute of Medical Science, University of Tokyo

Division name

surgery and Bioengineering

Zip code


Address


TEL


Homepage URL


Email

kanamoto@ims.u-tokyo.ac.jp


Sponsor or person

Institute

Institute of Medical Science, University of Tokyo

Institute

Department

Personal name



Funding Source

Organization

Government

Organization

Division

Category of Funding Organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2007 Year 07 Month 30 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2007 Year 07 Month 24 Day

Date of IRB


Anticipated trial start date

2007 Year 07 Month 01 Day

Last follow-up date

2008 Year 03 Month 01 Day

Date of closure to data entry

2008 Year 03 Month 01 Day

Date trial data considered complete

2008 Year 04 Month 01 Day

Date analysis concluded

2008 Year 04 Month 01 Day


Other

Other related information



Management information

Registered date

2007 Year 07 Month 30 Day

Last modified on

2008 Year 07 Month 30 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000000939


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name